Southern Acids (M) Berhad Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Southern Acids (M) Berhad şirketinin toplam hissedar öz sermayesi MYR870.9M ve toplam borcu MYR20.6M olup, bu da borç-öz sermaye oranını 2.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla MYR1.0B ve MYR144.5M dir. Southern Acids (M) Berhad 'in FAVÖK'ü MYR35.3M faiz karşılama oranı 41.2 dur. Şirketin MYR381.4M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

2.4%

Borç/özkaynak oranı

RM 20.60m

Borç

Faiz karşılama oranı	41.2x
Nakit	RM 381.40m
Eşitlik	RM 870.92m
Toplam yükümlülükler	RM 144.53m
Toplam varlıklar	RM 1.02b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Southern Acids (M) Berhad's (KLSE:SAB) Soft Earnings Are Actually Better Than They Appear

Mar 03

If You Like EPS Growth Then Check Out Southern Acids (M) Berhad (KLSE:SAB) Before It's Too Late

May 27

The Returns At Southern Acids (M) Berhad (KLSE:SAB) Aren't Growing

Apr 19

Are Strong Financial Prospects The Force That Is Driving The Momentum In Southern Acids (M) Berhad's KLSE:SAB) Stock?

Feb 24

Returns On Capital At Southern Acids (M) Berhad (KLSE:SAB) Paint An Interesting Picture

Jan 13

What Can We Learn About Southern Acids (M) Berhad's (KLSE:SAB) CEO Compensation?

Dec 15

Southern Acids (M) Berhad (KLSE:SAB) Share Prices Have Dropped 14% In The Last Three Years

Nov 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SAB 'nin kısa vadeli varlıkları ( MYR614.0M ) kısa vadeli yükümlülüklerini ( MYR109.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: SAB şirketinin kısa vadeli varlıkları ( MYR614.0M ) uzun vadeli yükümlülüklerini ( MYR35.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SAB şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: SAB şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 2.4% seviyesine yükseldi.

Borç Kapsamı: SAB 'nin borcu işletme nakit akışı ( 110.5% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: SAB 'in borcuna ilişkin faiz ödemeleri EBIT ( 41.2 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Southern Acids (M) Berhad Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New minor risk - Market cap size

Upcoming dividend of RM0.05 per share

New major risk - Revenue and earnings growth

Full year 2024 earnings released: EPS: RM0.10 (vs RM0.24 in FY 2023)

Southern Acids (M) Berhad, Annual General Meeting, Aug 26, 2024

New minor risk - Market cap size

Full year 2024 earnings released: EPS: RM0.10 (vs RM0.24 in FY 2023)

Southern Acids (M) Berhad Announces Redesignation of Chung Kin Mun from Independent Director to Non Independent and Non Executive Director

Third quarter 2024 earnings released: EPS: RM0.033 (vs RM0.12 in 3Q 2023)

Southern Acids (M) Berhad Announces Redesignation of Stephen Wan Yeng Leong from Member of Audit Committee to Independent and Non Executive Chairman of Audit Committee

Southern Acids (M) Berhad (KLSE:SAB) entered into agreement to acquire remaining 10% stake in Firstview Development Sdn Bhd from Low Mong Hua Sdn Berhad for RM 23.5 million.

Second quarter 2024 earnings released: RM0.039 loss per share (vs RM0.081 profit in 2Q 2023)

Upcoming dividend of RM0.05 per share at 1.5% yield

Southern Acids (M) Berhad Announces Appointment of Deborah Deb-Bie Choa as Independent and Non Executive Director

First quarter 2024 earnings released: EPS: RM0.067 (vs RM0.11 in 1Q 2023)

New minor risk - Market cap size

Full year 2023 earnings released: EPS: RM0.24 (vs RM0.69 in FY 2022)

Southern Acids (M) Berhad, Annual General Meeting, Aug 30, 2023

Southern Acids (M) Berhad Announces Cessation of Office of Madam Leong So Seh as Member of Nomination and Remuneration Committee

Full year 2023 earnings released: EPS: RM0.24 (vs RM0.69 in FY 2022)

Outhern Acids (M) Berhad Recommends Single Tier Final Dividend in Respect of the Financial Year Ended 31 March 2023

Southern Acids (M) Berhad's (KLSE:SAB) Soft Earnings Are Actually Better Than They Appear

Third quarter 2023 earnings released: EPS: RM0.12 (vs RM0.20 in 3Q 2022)

Second quarter 2023 earnings released: EPS: RM0.082 (vs RM0.13 in 2Q 2022)

Price target decreased to RM3.40

Insufficient new directors

Upcoming dividend of RM0.05 per share

Full year 2022 earnings released: EPS: RM0.69 (vs RM0.27 in FY 2021)

Southern Acids (M) Berhad Announces Final Dividend, Payable on 28 Nov. 2022

Southern Acids (M) Berhad Recommends Single Tier Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to RM3.40

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2022 earnings released: EPS RM0.17 (vs RM0.13 in 1Q 2021)

Upcoming dividend of RM0.05 per share

Full year 2021 earnings released: EPS RM0.27 (vs RM0.23 in FY 2020)

Price target decreased to RM3.40

Full year 2021 earnings released: EPS RM0.27 (vs RM0.23 in FY 2020)

If You Like EPS Growth Then Check Out Southern Acids (M) Berhad (KLSE:SAB) Before It's Too Late

Southern Acids (M) Berhad Recommends Final Dividend for the Year Ended March 31, 2021

The Returns At Southern Acids (M) Berhad (KLSE:SAB) Aren't Growing

Third quarter 2021 earnings released: EPS RM0.041 (vs RM0.076 in 3Q 2020)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Southern Acids (M) Berhad's KLSE:SAB) Stock?

Returns On Capital At Southern Acids (M) Berhad (KLSE:SAB) Paint An Interesting Picture

What Can We Learn About Southern Acids (M) Berhad's (KLSE:SAB) CEO Compensation?

New 90-day high: RM3.88

Southern Acids (M) Berhad Announces Appointment of Tan Sri Datuk Seri Panglima Sulong Bin Matjeraie as Independent and Non Executive Ember of Audit Committee

Second quarter 2021 earnings released: EPS RM0.06

Southern Acids (M) Berhad (KLSE:SAB) Share Prices Have Dropped 14% In The Last Three Years

New 90-day high: RM3.80

Southern Acids (M) Berhad Announces the Resignation of Encik Teo Leng as Independent and Non Executive Member of Audit Committee

New 90-day high: RM3.72

Upcoming Dividend of RM0.05 Per Share

First quarter earnings released

New 90-day high - RM3.68

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin